Volume 30, Number 3—March 2024
Research
Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan
Figure 4
![Vaccine effectiveness against death among all age groups in a population-based evaluation of vaccine effectiveness against SARS-CoV-2 infection, severe illness, and death, Taiwan, March 22, 2021–September 30, 2022. The study investigated various vaccine types: mRNA (Pfizer-BioNTech BNT162b2 [https://www.pfizer.com] and Moderna mRNA-1273 [https://www.modernatx.com]), protein subunit (Medigen MVC-COV1901 [https://www.medigenvac.com]), and viral vector-based vaccines (Oxford-AstraZeneca AZD1222 [https://www.astrazeneca.com]). The forest plot demonstrates effectiveness of different vaccination regimens status against death for all age groups. Blue diamonds indicate percentage effectiveness; bars indicate 95% CIs. AZ, AstraZeneca vaccine.](/eid/images/23-0893-F4.jpg)
Figure 4. Vaccine effectiveness against death among all age groups in a population-based evaluation of vaccine effectiveness against SARS-CoV-2 infection, severe illness, and death, Taiwan, March 22, 2021–September 30, 2022. The study investigated various vaccine types: mRNA (Pfizer-BioNTech BNT162b2 [https://www.pfizer.com] and Moderna mRNA-1273 [https://www.modernatx.com]), protein subunit (Medigen MVC-COV1901 [https://www.medigenvac.com]), and viral vector-based vaccines (Oxford-AstraZeneca AZD1222 [https://www.astrazeneca.com]). The forest plot demonstrates effectiveness of different vaccination regimens status against death for all age groups. Blue diamonds indicate percentage effectiveness; bars indicate 95% CIs. AZ, AstraZeneca vaccine.